Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.030
+0.035 (3.56%)
At close: Oct 24, 2025, 4:00 PM EDT
1.040
+0.010 (0.97%)
Pre-market: Oct 27, 2025, 4:11 AM EDT
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$1,077,614
Profits / Employee
-$2,921,513
Market Cap
13.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | -59 | -88.06% |
| Dec 31, 2022 | 67 | 11 | 19.64% |
| Dec 31, 2021 | 56 | 12 | 27.27% |
| Dec 31, 2020 | 44 | 16 | 57.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MRKR News
- 20 days ago - Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - GlobeNewsWire
- 2 months ago - Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Marker Therapeutics Stock Drops After Report About Lymphoma Treatment - Benzinga
- 2 months ago - Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma - GlobeNewsWire
- 3 months ago - Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 4 months ago - Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma - GlobeNewsWire
- 5 months ago - Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma - GlobeNewsWire
- 5 months ago - Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - GlobeNewsWire